Decision Benefits Medicaid Patients with Chronic Wounds

NEWPORT NEWS, Virginia (January 1, 2014) – Effective immediately, the Ohio Department of Medicaid will provide coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds. This decision is consistent with many recent actions taken by ODM to provide Ohio citizens “quality coordinated care at a value to the taxpayers” by implementing innovative and cost effective healthcare solutions.

“We applaud the decision by the Ohio Department of Medicaid to cover this limb and life-saving product for their 2.4 million Medicaid recipients,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Ohio residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these types of ulcers.

Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

About 21% of adults in Ohio that are over 65 have been told they have Type 2 diabetes. The number of residents with Type 2 diabetes has grown to an estimated 1.2 million. Treatment costs the State $6.0 Billion a year. “We will work tirelessly with the medical institutions and practitioners in Ohio to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing.

Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.

For more information on ODM coverage, please go to:

Please note that while coverage is effective January 1, 2014, the ODM system will not indicate this on the “Provider-Administered Pharmaceuticals” fee schedule until the file is updated on or about 2/1/14. ODM has suggested that providers hold TheraSkin claim submissions until the fees are loaded into ODM’s claims processing system; coverage however will be backdated to 1/1/14.